Phase II TACTI-002 Trial: Updated Results With Eftilagimod Alpha Plus Pembrolizumab as First-line Therapy in Advanced NSCLC

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
Results from the phase II TACTI-002 trial of the LAG-3 fusion protein eftilagimod alpha in combination with pembrolizumab showed promising durable activity in treatment-naïie patients with advanced NSCLC unselected for PD-L1.
Format: Microsoft PowerPoint (.ppt)
File Size: 181 KB
Released: June 7, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings